ACADIA PHARMACEUTICALS INC
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
ACAD$16.50-22.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Cash and cash equivalents | $177,695 | $319,589 |
| Investment securities, available-for-sale | 641,991 | 436,404 |
| Accounts receivable, net | 121,457 | 98,739 |
| Interest and other receivables | 26,774 | 5,956 |
| Inventory | 34,670 | 21,949 |
| Prepaid expenses | 59,526 | 55,681 |
| Total current assets | 1,062,113 | 938,318 |
| Property and equipment, net | 7,511 | 4,215 |
| Operating lease right-of-use assets | 47,354 | 46,571 |
| Intangible assets, net | 108,893 | 119,782 |
| Restricted cash | 7,845 | 8,770 |
| Long-term inventory | 76,704 | 69,741 |
| Deferred tax assets | 249,879 | — |
| Other assets | 3,896 | 359 |
| Total assets | $1,564,195 | $1,187,756 |
| Liabilities and stockholders’ equity | ||
| Accounts payable | $10,903 | $16,192 |
| Accrued liabilities | 266,211 | 378,678 |
| Total current liabilities | 277,114 | 394,870 |
| Operating lease liabilities | 40,554 | 42,037 |
| Other long-term liabilities | 19,137 | 18,056 |
| Total liabilities | 336,805 | 454,963 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 5,000,000 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024 | — | — |
| Common stock, $0.0001 par value; 225,000,000 shares authorized at December 31, 2025 and 2024; 170,309,376 shares and 166,708,856 shares issued and outstanding at December 31, 2025 and 2024, respectively | 16 | 16 |
| Additional paid-in capital | 3,039,315 | 2,936,871 |
| Accumulated deficit | (1,813,386) | (2,204,386) |
| Accumulated other comprehensive income | 1,445 | 292 |
| Total stockholders’ equity | 1,227,390 | 732,793 |
| Total liabilities and stockholders’ equity | $1,564,195 | $1,187,756 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.